XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.3

Commitments and Contingencies - License Agreements (Details)					1 Months Ended	12 Months Ended
	Oct. 27, 2023 shares	Jul. 19, 2023 $ / shares shares	Sep. 07, 2021 USD ($) shares	Nov. 01, 2019 USD ($) shares	Mar. 31, 2023	Jun. 30, 2024 USD ($)	Mar. 27, 2023 item
Commitments and Contingencies
Interest expense						$ 49,808
TheraCour Pharma Inc
Commitments and Contingencies
Percentage of net sales allocated for royalty payments (in percent)						15.00%
Related party | KMPL
Commitments and Contingencies
Percentage of clinical trials fees					30.00%
Percentage of royalty fee					70.00%
Number of clinical test drug candidates granted for the use, sale, or offer of sale in India | item							2
Related party | TheraCour Pharma Inc
Commitments and Contingencies
Cash upon completion of Phase I Clinical Trials				$ 1,500,000
Cash upon completion of Phase II Clinical Trials				2,500,000
Cash upon completion of Phase III Clinical Trials				$ 5,000,000
Stock Issued During Period, Shares, New Issues | shares				75,000
Number of shares upon principle of note convertible | shares	331,859
Gain on extinguishment						$ 49,808
Percentage of net sales allocated for royalty payments (in percent)				15.00%
Related party | TheraCour Pharma Inc | Unsecured promissory note
Commitments and Contingencies
Interest rate per annum (as a percent)		12.00%
Series A Preferred Stock | TheraCour Pharma Inc
Commitments and Contingencies
Number of shares upon principle of note convertible | shares		331,859
Debt instrument, conversion stock, par value | $ / shares		$ 0.00001
Series A Preferred Stock | Related party
Commitments and Contingencies
Shares value upon initiation of Phase III Clinical Trials			$ 100,000
Series A Preferred Stock | Related party | TheraCour Pharma Inc
Commitments and Contingencies
Cash upon completion of Phase I Clinical Trials			2,000,000
Cash upon completion of Phase II Clinical Trials			2,500,000
Cash upon completion of Phase III Clinical Trials			$ 5,000,000
Number of shares issuable upon execution of agreement | shares			100,000
Threshold Period for Issuance of Shares Upon Execution of Agreement			30 days
Stock Issued During Period Value New Issues Initiation Of Phase1 Clinical Trials			$ 1,500,000
Shares value upon completion of Phase III Clinical Trials			$ 500,000
Stock Issued During Period, Shares, New Issues | shares			50,000
Percentage of net sales allocated for royalty payments (in percent)			15.00%

X

- Definition

The line item information about commitment and contingencies.

+ References

No definition available.

+ Details

Name:	nnvc_CommitmentsAndContingenciesLineItems
Namespace Prefix:	nnvc_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The number of clinical test drug candidates granted for the use, sale, or offer of sale in India.

+ References

No definition available.

+ Details

Name:	nnvc_NumberOfClinicalTestDrugCandidatesGrantedForUseSaleOrOfferOfSaleInIndia
Namespace Prefix:	nnvc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The number of shares issuable upon execution of agreement.

+ References

No definition available.

+ Details

Name:	nnvc_NumberOfSharesIssuableUponExecutionOfAgreement
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of clinical trials manager fee.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfClinicalTrialsFees
Namespace Prefix:	nnvc_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty expense calculated as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix:	nnvc_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of royalty fee paid.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfRoyaltyFee
Namespace Prefix:	nnvc_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of shares of stock issued during period shares new issues principle of note convertible.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodSharesNewIssuesPrincipleOfNoteConvertible
Namespace Prefix:	nnvc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase I clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase II clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase III clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

It represents the amount of stock issued during period, value, new issues, upon completion of phase III clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCompletionOfPhase3ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

It represents the amount of stock issued during period, value, new issues, upon initiation of phase I clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesInitiationOfPhase1ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

It represents the amount of stock issued during period, value, new issues, upon initiation of phase III clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesInitiationOfPhase3ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The threshold period for issuance of shares upon execution of agreement.

+ References

No definition available.

+ Details

Name:	nnvc_ThresholdPeriodForIssuanceOfSharesUponExecutionOfAgreement
Namespace Prefix:	nnvc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentConvertibleStockPriceTrigger
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-4

+ Details

Name:	us-gaap_GainsLossesOnExtinguishmentOfDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-6

+ Details

Name:	us-gaap_InterestExpenseDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionRate
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=nnvc_KarveerMeditechPvt.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=nnvc_UnsecuredPromissoryNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: